MLC1 antibody identified as possible trigger of rare neurological autoimmune disorder

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease that targets the central nervous system, specifically the brain, spinal cord, and optic nerve. The condition arises when the immune system mistakenly attacks astrocytes—glial cells that provide structural support and regulate the chemical environment of nerve tissue—leading to inflammation and damage in these critical areas.

In 2005, researchers identified that the majority of NMOSD patients carry a serum antibody directed against aquaporin‑4, a water channel protein expressed on astrocytes. This discovery clarified the disease’s underlying mechanism and has guided the development of targeted therapies that inhibit the antibody’s activity, improving diagnostic accuracy and patient outcomes. Continued research into aquaporin‑4 and related immune pathways remains essential for refining treatment strategies and advancing care for those affected by NMOSD.